Epidermolysis Bullosa DystrophicaNCT03241628
Proof of Concept Study for a Dressing Glove
An observational study of Epidermolysis Bullosa Dystrophica, run by Guy's and St Thomas' NHS Foundation Trust at 1 site in United Kingdom.
Trial summary
Epidermolysis Bullosa (EB) is a group of genetic conditions causing extensive, painful skin blisters and wounds. Four main types of EB are recognised, which all affect the hands but those patients usually requiring hand therapy interventions have Recessive Dystrophic EB (RDEB). Read more about this study
- Who is it for?
- Ages 1 year and older
- Conditions the study is for
- Epidermolysis Bullosa Dystrophica
- What is being tested?
- Dressing Glove
- Type of treatment
- Medical device
- How many people
- 14 participants
- Where
- 1 siteUnited Kingdom
- Study dates
- 3 May 2017to 31 Jan 2018
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 1 year and older
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Study population: Adults and children with RDEB and hand deformaties
Who may be able to join
- Adults (over the age of seventeen) with RDEB who use or have used dressings and bandages on their hands.
- Parents/carers of adults over the age of 17 with RDEB who use or have used dressings and bandages on their hands.
- Parents/carers of babies, children and young people (up to the age of 17) with RDEB who use or have used dressings and bandages on their hands.
- Babies, children and young people (age 1-17 years) with RDEB who use or have used dressings and bandages on their hands.
- Able to communicate in English, verbally and in writing
- Able to make an informed decision to participate and to give written consent
- Not participating in concurrent clinical studies
Who cannot join
- Babies aged less than 1 year old
- Not able to communicate in English, verbally and in writing
- Not able to make an informed decision to participate and to give written consent
- Participating in concurrent clinical studies
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Generation and Evaluation of Hand Therapy Devices for Epidermolysis Bullosa (GLOVE Project): Proof of Concept Study for a Dressing Glove
Epidermolysis Bullosa (EB) is a group of genetic conditions causing extensive, painful skin blisters and wounds. Four main types of EB are recognised, which all affect the hands but those patients usually requiring hand therapy interventions have Recessive Dystrophic EB (RDEB).
The proof of concept study is part of the GLOVE (Generation and evaLuation Of hand therapy deVices for Epidermolysis bullosa) project. The project aims (i) to develop two hand therapy devices; a disposable dressing glove and splint glove to manage blisters, wounds and contractures that occur on the hands of people with RDEB (ii) to design and implement the Hand Therapy Online (HTO) electronic patient record system and (iii) to determine the cost effectiveness of the devices and the HTO system.
Read more
The proof of concept study focuses on testing the clinical performance and cost effectiveness of the dressing glove when compared with conventional dressings.
Recruited GLOVE participants will be invited to participate in the 14 week study, conducted using a quasi-experimental, n-of-1 research design. Patients who have not participated in GLOVE will also be invited to join. Participants will be asked to follow their usual dressing regime for six weeks. At week 7, they will be given several pairs of dressing gloves to replace their usual dressings, or starting to wear the glove if they avoid dressings normally and familiarise themselves. If participants usually wear their gloves to maintain their web spaces, they will wear these on top of the dressing glove to help assess compatibility.
Participants will provide feedback twice a week from week 7 on the dressing glove by answering 12 questions (TELER indicators) validated in the Pilot study (REC no: 16/LO/1046) using the HTO system. Data from the HTO system will be used by the Health Economist to determine the dressing glove and HTO's cost effectiveness.
Read the detailed description
Principal research question/objective How effective is the disposable dressing glove when compared with the normal dressings and bandages used by the participants with RDEB based on 12 validated patient outcomes indicators that measure observations of hand function, device use, symptoms, and problems and limitations?
Secondary research questions Is the disposable dressing glove compatible with the SkinniesTM Web Spacer glove or any other make of glove used by the participants with RDEB to maintain their web spaces? Would you like to continue wearing the dressing glove? Is there anything else you(the participants) would like to tell us about the dressing glove?
Study design and methodology Study Design The proof of concept study of the dressing glove will be conducted using a quasi-experimental, n-of-1 research design drawn from the Medical Research Council Guidance for the design of complex interventions (MRC 2008). The reason for using this research design is due to a small sample of a small population of people with Recessive Dystrophic Epidermolysis Bullosa (RDEB). In addition, hand deformities amongst people with RDEB vary from one individual to another. Treatment and care also involve more than one intervention administered concurrently, for example wounds dressings, web-spacer gloves and splints. The researchers need to study the performance of these devices individually and together in terms of their effectiveness in delaying disease progression deformities.
The n-of-1 study design will enable investigation of the dressing glove performance against pre-determined performance criteria (12 patient recorded outcome measures on the HTO system) at the individual and group level with each participant acting as their own control.
Sample Size The sample for the GLOVE project is 14 participants. To date, seven adults and six children from pre-school age to school age have been recruited to the project from the project's two NHS sites, Guy's and St Thomas' (GSTT) NHS Foundation Trust and Great Ormond Street Hospital (GOSH) NHS Foundation Trust respectively. All the GLOVE participants will be invited to participate in the proof of concept study, subject to meeting the inclusion criteria.
Method of Recruitment The EB clinical team (GSTT; GOSH) will identify potential participants who meet the inclusion criteria for the study. The KCL research team will send a letter of invitation to these participants containing age appropriate information sheets, assent and consent forms (Letter of invitation V2 10 Jan 2017). The letter also has the contact details for the King's College Research team should the participants require further information. Participants will have a minimum of a week to decide if they would like to participate in the study. They will be invited to return the reply slip to the EB clinicians who will return them to the Chief Investigator. The EB clinicians will recruit and consent those participants who have not be involved in the GLOVE project to date. Those who have will be recruited and consented by the KCL research team. Adults (18 years and over) or their carers will be asked to provide written informed consent. Children (7-17 years) will also be asked to provide written informed consent. Their parents will also be asked to provide their written consent for their child to participate. Children aged 4-6 will be invited to provide written assent, once their parents have agreed to this. The parents will also provide their written consent, as will the parents of babies and toddlers. The consent and assent forms will be returned to the Chief Investigator at King's College London and kept in a locked cupboard, separated from the data in order to maintain data anonymity.
Conduct of the Proof of Concept Study The study will take place over 14 weeks. Participants will be asked to follow their usual dressing regime for six weeks. At week 7, they will be given several pairs of dressing gloves to familiarise themselves with. At week 8, participants will replace their usual dressings and bandages with the dressing glove or start to wear the gloves if they avoid dressings normally. If participants usually wear their gloves to maintain their web spaces, they will continue to wear these on top of the dressing glove to help assess compatibility.
Method of data collection Participants will provide feedback twice a week on the dressing glove by answering 12 questions (TELER indicators) using the Hand Therapy Online system (HTO), which is an electronic patient record system (HTO indicators V2 10 Jan 2017; Patient Guide V3). The indicators and the HTO were validated in the Pilot study (REC no: 16/LO/1046).
There are three types of measurements 1) TELER indicators, (2) physical measurements (3) measures of cost. The TELER indicators are a tool to measure observations of hand function, device use, symptoms and problems/limitations. The indicators measure clinically meaningful changes comprising an improvement, deterioration or no change in hand function from one time point to another. Each indicator is on a scale of six clinical steps or 'codes'. Code 5 is best case scenario or the treatment goal and code 0 is worst case scenario (i.e. the problem to be avoided) with codes 4, 3, 2 and 1 being clinically meaningful steps towards or away from the treatment goal.
GLOVE participants recruited to the study will be trained by the KCL researchers to use HTO system to provide feedback twice a week on the dressing glove by answering the TELER indicators for the dressing glove validated in the pilot study (REC no: 16/LO/1046).
The data from the HTO system will inform the methodology for measuring the cost effectiveness of the dressing glove.
Data analysis Numerical data analysis comprises automated calculation of patient specific index numbers within the digitised system (Deficit Index, Improvement Index, Maintenance Index, and Effectiveness Index) and two group indices (Health Status Index and Health Gain Index). An analysis of the costs of standard care versus the intervention will also be performed taking into account the use of products, time taken for wound care, and impact of wound care on daily living.
Researcher bias will be minimised by their minimal direct contact with the data collection process. In addition no attempt has been made to design out any confounding variables, thereby replicating the situations in which patients are normally treated.
Report writing and dissemination The Chief Investigator will take responsibility for writing the reports during the study and disseminating the findings, positive and negative, through publications and conference presentations.
The findings from the study will enable generalisations to be made to the wider population of RDEB patients with similar disease progression hand deformities that require the constant use of wound dressing and web-spacer gloves (Research Protocol V2 10 Jan 2017.
- Conditions
- Epidermolysis Bullosa Dystrophica
- Being tested
- Dressing Glove
- Keywords
- Skin blisters, Finger webbing, Finger contracture, Hand contracture
- Medical subject headings
- Epidermolysis Bullosa Dystrophica, Blister
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Dressing GloveDevice
Viscose dressing glove
| Study group | Role | What they receive |
|---|---|---|
| Dressing Glove | Fitting bespoke dressing gloves (viscose Class 1 medical device) and evaluating dressing glove performance in the management of blisters using patient recorded outcome measures. The aim is to obtain proof of concept data for the dressing glove as an acceptable alternative to patch work dressings held in place with bandages.
The study protocol recommends a daily change of the dressing glove but the patients also contribute their preference for frequency of dressing changes. Receives: Device: Dressing Glove |
What is being measured
The primary outcome is the main question the study is designed to answer.
Effectiveness of disposable dressing glove compared with normal dressings and bandages
Dressing glove performance against pre-determined performance criteria (12 patient recorded outcome measures on the HTO system) at the individual and group level with each participant acting as their own control.
Measured: 14 weeks
Secondary outcomes (1)
Compatibility with the SkinniesTM Web Spacer glove
Determination of the compatibility of disposable dressing glove with the SkinniesTM Web Spacer glove or any other make of glove used by the participants with RDEB to maintain their web spaces
Measured: 14 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted7 Aug 2017
- Study start3 May 2017
- Primary completion31 Jan 2018
- Study completion31 Jan 2018
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Epidermolysis Bullosa DystrophicaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case only
- Time perspective
- Prospective
- Enrolment
- 14 participants (actual)
Sponsor and investigators
- Lead sponsor
- Guy's and St Thomas' NHS Foundation Trust
- Sponsor type
- University, hospital or other
- Collaborators
- King's College London, Cardiff University, University of Surrey
- Responsible party
- Sponsor
- Investigators
- Patricia Grocott, PhD, Principal investigator, NIHR i4i
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03241628
- Sponsor's protocol ID
- 17/LO/0420
- Status last verified
- Feb 2018
- First submitted
- 31 Jul 2017
- Last updated
- 15 Feb 2018
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 15 Feb 2018. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Generation and Evaluation of Hand Therapy Devices for Epidermolysis Bullosa (GLOVE Project): Proof of Concept Study for a Dressing Glove
- ClinicalTrials.gov ID
- NCT03241628
- Acronym / sponsor ID
- 17/LO/0420
- Conditions
- Epidermolysis Bullosa Dystrophica
- Keywords
- Skin blisters, Finger webbing, Finger contracture, Hand contracture
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 14 participants (actual)
- Lead sponsor
- Guy's and St Thomas' NHS Foundation TrustUniversity, hospital or other
- Collaborators
- King's College London, Cardiff University, University of Surrey
- Study start
- 3 May 2017 (actual)
- Primary completion
- 31 Jan 2018 (actual)
- Study completion
- 31 Jan 2018 (actual)
- First posted
- 7 Aug 2017 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Epidermolysis Bullosa (EB) is a group of genetic conditions causing extensive, painful skin blisters and wounds. Four main types of EB are recognised, which all affect the hands but those patients usually requiring hand therapy interventions have Recessive Dystrophic EB (RDEB).
The proof of concept study is part of the GLOVE (Generation and evaLuation Of hand therapy deVices for Epidermolysis bullosa) project. The project aims (i) to develop two hand therapy devices; a disposable dressing glove and splint glove to manage blisters, wounds and contractures that occur on the hands of people with RDEB (ii) to design and implement the Hand Therapy Online (HTO) electronic patient record system and (iii) to determine the cost effectiveness of the devices and the HTO system.
The proof of concept study focuses on testing the clinical performance and cost effectiveness of the dressing glove when compared with conventional dressings.
Recruited GLOVE participants will be invited to participate in the 14 week study, conducted using a quasi-experimental, n-of-1 research design. Patients who have not participated in GLOVE will also be invited to join. Participants will be asked to follow their usual dressing regime for six weeks. At week 7, they will be given several pairs of dressing gloves to replace their usual dressings, or starting to wear the glove if they avoid dressings normally and familiarise themselves. If participants usually wear their gloves to maintain their web spaces, they will wear these on top of the dressing glove to help assess compatibility.
Participants will provide feedback twice a week from week 7 on the dressing glove by answering 12 questions (TELER indicators) validated in the Pilot study (REC no: 16/LO/1046) using the HTO system. Data from the HTO system will be used by the Health Economist to determine the dressing glove and HTO's cost effectiveness.
Detailed description
Principal research question/objective How effective is the disposable dressing glove when compared with the normal dressings and bandages used by the participants with RDEB based on 12 validated patient outcomes indicators that measure observations of hand function, device use, symptoms, and problems and limitations?
Secondary research questions Is the disposable dressing glove compatible with the SkinniesTM Web Spacer glove or any other make of glove used by the participants with RDEB to maintain their web spaces? Would you like to continue wearing the dressing glove? Is there anything else you(the participants) would like to tell us about the dressing glove?
Study design and methodology Study Design The proof of concept study of the dressing glove will be conducted using a quasi-experimental, n-of-1 research design drawn from the Medical Research Council Guidance for the design of complex interventions (MRC 2008). The reason for using this research design is due to a small sample of a small population of people with Recessive Dystrophic Epidermolysis Bullosa (RDEB). In addition, hand deformities amongst people with RDEB vary from one individual to another. Treatment and care also involve more than one intervention administered concurrently, for example wounds dressings, web-spacer gloves and splints. The researchers need to study the performance of these devices individually and together in terms of their effectiveness in delaying disease progression deformities.
The n-of-1 study design will enable investigation of the dressing glove performance against pre-determined performance criteria (12 patient recorded outcome measures on the HTO system) at the individual and group level with each participant acting as their own control.
Sample Size The sample for the GLOVE project is 14 participants. To date, seven adults and six children from pre-school age to school age have been recruited to the project from the project's two NHS sites, Guy's and St Thomas' (GSTT) NHS Foundation Trust and Great Ormond Street Hospital (GOSH) NHS Foundation Trust respectively. All the GLOVE participants will be invited to participate in the proof of concept study, subject to meeting the inclusion criteria.
Method of Recruitment The EB clinical team (GSTT; GOSH) will identify potential participants who meet the inclusion criteria for the study. The KCL research team will send a letter of invitation to these participants containing age appropriate information sheets, assent and consent forms (Letter of invitation V2 10 Jan 2017). The letter also has the contact details for the King's College Research team should the participants require further information. Participants will have a minimum of a week to decide if they would like to participate in the study. They will be invited to return the reply slip to the EB clinicians who will return them to the Chief Investigator. The EB clinicians will recruit and consent those participants who have not be involved in the GLOVE project to date. Those who have will be recruited and consented by the KCL research team. Adults (18 years and over) or their carers will be asked to provide written informed consent. Children (7-17 years) will also be asked to provide written informed consent. Their parents will also be asked to provide their written consent for their child to participate. Children aged 4-6 will be invited to provide written assent, once their parents have agreed to this. The parents will also provide their written consent, as will the parents of babies and toddlers. The consent and assent forms will be returned to the Chief Investigator at King's College London and kept in a locked cupboard, separated from the data in order to maintain data anonymity.
Conduct of the Proof of Concept Study The study will take place over 14 weeks. Participants will be asked to follow their usual dressing regime for six weeks. At week 7, they will be given several pairs of dressing gloves to familiarise themselves with. At week 8, participants will replace their usual dressings and bandages with the dressing glove or start to wear the gloves if they avoid dressings normally. If participants usually wear their gloves to maintain their web spaces, they will continue to wear these on top of the dressing glove to help assess compatibility.
Method of data collection Participants will provide feedback twice a week on the dressing glove by answering 12 questions (TELER indicators) using the Hand Therapy Online system (HTO), which is an electronic patient record system (HTO indicators V2 10 Jan 2017; Patient Guide V3). The indicators and the HTO were validated in the Pilot study (REC no: 16/LO/1046).
There are three types of measurements 1) TELER indicators, (2) physical measurements (3) measures of cost. The TELER indicators are a tool to measure observations of hand function, device use, symptoms and problems/limitations. The indicators measure clinically meaningful changes comprising an improvement, deterioration or no change in hand function from one time point to another. Each indicator is on a scale of six clinical steps or 'codes'. Code 5 is best case scenario or the treatment goal and code 0 is worst case scenario (i.e. the problem to be avoided) with codes 4, 3, 2 and 1 being clinically meaningful steps towards or away from the treatment goal.
GLOVE participants recruited to the study will be trained by the KCL researchers to use HTO system to provide feedback twice a week on the dressing glove by answering the TELER indicators for the dressing glove validated in the pilot study (REC no: 16/LO/1046).
The data from the HTO system will inform the methodology for measuring the cost effectiveness of the dressing glove.
Data analysis Numerical data analysis comprises automated calculation of patient specific index numbers within the digitised system (Deficit Index, Improvement Index, Maintenance Index, and Effectiveness Index) and two group indices (Health Status Index and Health Gain Index). An analysis of the costs of standard care versus the intervention will also be performed taking into account the use of products, time taken for wound care, and impact of wound care on daily living.
Researcher bias will be minimised by their minimal direct contact with the data collection process. In addition no attempt has been made to design out any confounding variables, thereby replicating the situations in which patients are normally treated.
Report writing and dissemination The Chief Investigator will take responsibility for writing the reports during the study and disseminating the findings, positive and negative, through publications and conference presentations.
The findings from the study will enable generalisations to be made to the wider population of RDEB patients with similar disease progression hand deformities that require the constant use of wound dressing and web-spacer gloves (Research Protocol V2 10 Jan 2017.
Study design
- Observational model
- Case only
- Time perspective
- Prospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Dressing Glove | – | Device: Dressing GloveFitting bespoke dressing gloves (viscose Class 1 medical device) and evaluating dressing glove performance in the management of blisters using patient recorded outcome measures. The aim is to obtain proof of concept data for the dressing glove as an acceptable alternative to patch work dressings held in place with bandages. The study protocol recommends a daily change of the dressing glove but the patients also contribute their preference for frequency of dressing changes. |
Who may qualify
- Ages
- 1 year and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
- Study population
- Adults and children with RDEB and hand deformaties
Key inclusion criteria (7 listed)
- Adults (over the age of seventeen) with RDEB who use or have used dressings and bandages on their hands.
- Parents/carers of adults over the age of 17 with RDEB who use or have used dressings and bandages on their hands.
- Parents/carers of babies, children and young people (up to the age of 17) with RDEB who use or have used dressings and bandages on their hands.
- Babies, children and young people (age 1-17 years) with RDEB who use or have used dressings and bandages on their hands.
- Able to communicate in English, verbally and in writing
Key exclusion criteria (4 listed)
- Babies aged less than 1 year old
- Not able to communicate in English, verbally and in writing
- Not able to make an informed decision to participate and to give written consent
- Participating in concurrent clinical studies
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Dressing GloveViscose dressing glove | Device | Dressing Glove |
Primary outcome
Effectiveness of disposable dressing glove compared with normal dressings and bandages
Time frame: 14 weeks
Dressing glove performance against pre-determined performance criteria (12 patient recorded outcome measures on the HTO system) at the individual and group level with each participant acting as their own control.
1 secondary outcome
Compatibility with the SkinniesTM Web Spacer glove
Time frame: 14 weeks
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 15 Feb 2018.
- Individual participant dataSharing planned: No
Related trials for Epidermolysis Bullosa Dystrophica
RecruitingPhase 2
A Phase 2 Study of TCP-25 Gel in Patients With Epidermolysis Bullosa, STEP-study
Epidermolysis Bullosa (EB), Dystrophic Epidermolysis Bullosa
RecruitingPhase 2
A Study to Evaluate ENERGI-F703EB Cream in Epidermolysis Bullosa
Epidermolysis Bullosa (EB), Junctional Epidermolysis Bullosa
RecruitingObservational study
A Study to Assess the Incidence of Skin Cancers in Patients With Epidermolysis Bullosa Receiving Filsuvez
Epidermolysis Bullosa, Dystrophic, Epidermolysis Bullosa, Junctional
Not yet recruitingPhase 4
Phase 4 Master Protocol for Patients Prescribed Prademagene Zamikeracel for the Treatment of Wounds
Epidermolysis Bullosa (EB), Recessive Dystrophic Epidermolysis Bullosa (RDEB)
Enrolling by invitationObservational study
A Long-Term Extension Study for Participants Previously Treated With EB-101 for the Treatment of RDEB
RDEB
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Patricia Grocott, PhD principal investigator
NIHR i4i
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Epidermolysis Bullosa Dystrophica, run by Guy's and St Thomas' NHS Foundation Trust at 1 site in United Kingdom.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 7 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 15 Feb 2018. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Effectiveness of disposable dressing glove compared with normal dressings and bandages (time frame: 14 weeks). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 15 Feb 2018.